Highly active antiretroviral therapy and hospital readmission: Comparison of a matched cohort

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Nosyk, Bohdan ^a   Sun, Huiying ^a   Li, Xin ^a,b   Palepu, Anita ^a,b   Anis, Aslam H ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CALCULATION; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DRUG USE; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; QUANTITATIVE ANALYSIS; RELIABILITY; SCORING SYSTEM; SOCIAL ASPECT; TREATMENT INDICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT READMISSION;

EID: 33750387803     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-146     Document Type: Article

References (29)

1. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH: Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction 2004, 99(3):361-8.
2. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, Schechter MT, Hogg RS: Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-9.
3. CASCADE Collaboration: Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Medicine 2000, 1:224-31.
4. Muga R, Egea JM, Sanvisens A, Arnal J, Tural C, Tor J, Rey-Joly C: Impact of injecting drug use on the interruption of antiretroviral therapies. J Epidemiol Community Health 2004, 58:286-7.
5. Lucas GM, Chaisson RE, Moore RD: Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. Journal of Acquired Immune Deficiency Syndromes 2003, 33:321-8.
6. Lucas GM: Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. Journal of Antimicrobial Chemotherapy. 2005; Feb 18.
7. Sendi PP, Bucher HC, Harr T, Craig BA, Schweitert M, Pfluger D, Gafni A, Battegay M: Cost-effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Ccohort Study AIDS 1999, 13(9):1115-22.
8. Miners AH, Sabin CA, Trueman P, Youle M, Mocroft A, Johnson M, Beck EJ: Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England. HIV Medicine 2001, 2:52-8.
9. Holmes WC: HIV/AIDS, utilities, and cost-effectiveness analysis: stepping toward the future. Med Decis Making 2002, 22(6):522-5.
10. Law MG, Li Y, McDonald AM, Cooper DA, Kaldor JM: Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS 2000, 14:197-201.
11. Moore R: HIV Therapy and prevention: economics and cost-effectiveness. Hopkins HIV Rep 1998, 10(5):10-1.
12. Grant RW, Charlebois ED, Wachter RM: Risk factors for early hospital readmission in patients with AIDS and pneumonia. J Gen Intern Med 1999, 14:531-6.
13. Palepu A, Sun H, Kuyper L, Schechter MT, O'Shaughnessy MV, Anis AH: Early hospital readmission in HIV-infected patients. J Gen Intern med 2003, 18:242-7.
14. Goldberg M, Graves J: The Greater Vancouver Regional District: On our streets and in our shelters: Results of the 2005 Greater Vancouver Homeless Count. 2005 [http://www.gvrd.bc.ca/homelessness/research.htm].
15. D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998, 17:2265-81.
16. Elad Y, French WJ, Shavelle DM, Parsons LS, Sada MJ, Every NR: Primary angioplasty and selection bias in patients presenting late (> 12 h) after onset of chest pain and ST elevation myocardial infarction. Journal of the American College of Cardiology 2002, 39(5):826-33.
17. Joffe MM, Rosenbaum PR: Invited Commentary: Propensity Scores. American Journal of Epidemiology 1999, 150(4):327-3.
18. Ezzy DM, Bartos MR, O de Visser R, Rosenthal DA: Antiretroviral uptake in Australia: medical, attitudinal and cultural correlates. International Journal of STD and AIDS 1998, 9:579-86.
19. Palepu A, Yip B, Miller C, Strathdee SA, O'Shaughnessy MV, Montaner JSG, Hogg RS: Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001, 15(3):423-4.
20. Turner BJ, Laine C, Cosler L, Hauck WW: Health care delivery with Antiretroviral adherence. J Gen Intern Med 2003, 18:248-57.
21. Sherer R, Pulvirenti J, Stieglitz K, Narra J, Jasek J, Green L, Moore B, Shott S, Cohen M: Hospitalization in HIV in Chicago. J Int Assoc Physicians AIDS Care (Chic III) Winter 2002, 1(1):26-33.
22. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B: Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004, 18:1429-33.
23. Bangsberg D, Tulsky JP, Hect RM, Moss AR: Protease Inhibitors in the Homeless. JAMA 1997, 278:63-65.
24. Bini T, Testa L, Chiesa E, et al.: Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. JAIDS 2000, 24:115-22.
25. Park-Wyllie LY, Scalera A, Tseng A, Rourke S: High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support? AIDS 2002, 16(7):1084-6.
26. Richter R, Micheals M, Carlson B, Coates T: Motivators and Barriers to Use of Combination Therapies in Patients with HIV Disease. In San Francisco: Centre for AIDS Prevention Studies University of California; 1998.
27. Catt S, Stygal J, Catalan J: Acceptance of Zidovudine (AZT) in early HIV disease: the role of health benefits. AIDS Care 1995, 7:229-35.
28. Mossar M, Lefevre F, Deutsche J, Wesch J, Glassroth J: Factors predicting compliance with prophylactic treatments among HIV positive patients. Int Conf AIDS 1993, 9(2):787. (abstract no. PO-D01-3418).
29. Rothman KJ, Greenland S: Modern Epidemiology. 2nd edition. Lippincott-Raven Publishers Philadelphia; 1998:155-7.